Depomed (DEPO) Misses Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Mizuho Securities Upgrades DepoMed Inc (DEPO) to Buy
May 9, 2016 7:37 AM EDTMizuho Securities upgraded DepoMed Inc (NASDAQ: DEPO) from Neutral to Buy with a price target of $19.00 (from $18.00), on increased takeout probability.
Analyst Irina Koffler commented, "DEPO posted unimpressive numbers in 1Q:16 and shares got dragged down with the group on Friday.... More
DepoMed (DEPO) PT Lowered to $21 at Piper Jaffray
May 6, 2016 9:09 AM EDTPiper Jaffray analyst David Amsellem lowered his price target on DepoMed Inc (NASDAQ: DEPO) to $21.00 (from $23.00) and reiterated a Overweight rating following Q1 results.
Amsellem commented, "Depomed reported adjusted diluted EPS of $0.12 on revenues of $105M, versus Street estimates of $0.17 and $107M, respectively... More
